Try Calculator
← Back to Compound Library IMMUNE

LL-37

LL-37 is the only cathelicidin antimicrobial peptide produced by the human body. It is a 37- amino acid peptide that serves as one of the immune system’s primary weapons against bacteria, viruses, fungi, and parasites. The name derives from its structure: it begins with two leucine amino acids (LL) and is 37 amino acids in length. The human body produces LL-37 from a precursor protein called hCAP-18 (human cationic antimicrobial protein 18 kDa). When the immune system detects a threat, enzymes cleave hCAP- 18 to release the active LL-37 peptide. This process occurs in neutrophils, macrophages, dendritic cells, natural killer cells, and epithelial cells throughout the body, particularly in the skin, lungs, and gastrointestinal tract. What makes LL-37 remarkable is its versatility. Unlike traditional antibiotics that target a single specific mechanism, LL-37 kills pathogens through multiple pathways, modulates the immune response, neutralizes bacterial toxins, promotes wound healing, and stimulates new blood vessel formation. This multifunctionality makes it difficult for pathogens to develop resistance against it. LL-37 has gained significant research attention as antibiotic resistance becomes an increasingly serious global health threat. The World Health Organization has identified antimicrobial resistance as one of the top ten threats to global health. LL-37 represents a fundamentally different approach to fighting infection because it works with the immune system rather than simply poisoning bacteria. LL-37 is a short, positively charged peptide with amphipathic character that supports interactions with anionic lipid surfaces and microbial envelope components. In biophysical studies, LL-37 adopts conformations consistent with membrane-associated states, enabling pore formation and membrane destabilization under defined conditions. Its activity is highly dependent on local milieu, including ionic strength, serum components, and membrane composition, making it a valuable model compound for studying context-dependent immunobiology.

Molecular Formula: C₂₀₅H₃₄₀N₆₀O₅₃

Molecular Weight: 4493.342 g/mol

Sequence: Leu-Leu-Gly-Asp-Phe-Phe-Arg-Lys-Ser-Lys-Glu-Lys-Ile-Gly-Lys-Glu-Phe-Lys- Arg-Ile-Val-Gln-Arg-Ile-Lys-Asp-Phe-Leu-Arg-Asn-Leu-Val-Pro-Arg-Thr-Glu-Ser

CAS Number: 154947-66-7

PubChem CID: 16198951

Synonyms: CAP-18, Cathelicidin, Antibacterial Peptide LL-37

Clinical trials have tested LL-37 topically for wound healing in venous leg ulcers with promising results. Injectable protocols are based primarily on community experience and preclinical research.

How It Works

Direct Antimicrobial Action: Membrane Disruption

LL-37 kills pathogens primarily by destroying their cell membranes. The peptide has a unique amphipathic structure: one side is attracted to water (hydrophilic) and the other side is attracted to fat (hydrophobic). This allows it to insert into the lipid membranes of bacteria and create pores that compromise membrane integrity. The process follows a well-characterized sequence:

human cell membranes are neutral

This mechanism is fundamentally different from conventional antibiotics. Most antibiotics target specific bacterial proteins or enzymes. Bacteria can develop resistance by mutating these targets. However, bacteria cannot easily change the basic structure of their cell membranes without losing viability. This is why antimicrobial peptides like LL-37 are considered less prone to resistance development. Biophysical studies indicate that LL-37 interacts with lipid bilayers through surface-associated mechanisms. Unlike classical barrel-stave or toroidal pore-forming peptides, LL-37 remains largely parallel to the membrane surface while inducing bilayer perturbation. Fluorescence spectroscopy, electron microscopy, and lipid bilayer modeling experiments suggest that LL-37 can induce membrane destabilization without complete fragmentation.

Immunomodulatory Functions

Beyond direct killing, LL-37 has extensive immunomodulatory effects that position it as a systems-level modulator of innate immune function:

bacterial toxin that triggers septic shock

chemotactic signaling via formyl peptide receptor-like 1 (FPRL1) and related pathways

longer during active infection

and tissue repair

epithelialization

and chemokine production

associated pathways such as pyroptosis in macrophage models, suggesting a role in balancing host defense with inflammatory control Notably, LL-37 does not affect the immune system in the same way at all times. Research in cell culture has shown that the inflammatory environment affects how cells of the immune system respond to LL-37. T-cells, for instance, increase their inflammatory actions in response to LL-37 when they are not activated but decrease inflammatory action when already activated. This indicates that LL-37 has potent homeostatic effects, helping to balance the immune response and prevent it from becoming overactive during infection.

Anti-Biofilm Activity

LL-37 also demonstrates significant anti-biofilm activity. Biofilms are communities of bacteria encased in a protective matrix that makes them extremely resistant to antibiotics—often 100 to 1,000 times more resistant than free-floating bacteria. LL-37 can penetrate and disrupt these biofilm structures, making the bacteria vulnerable to immune clearance. This has important implications for conditions such as chronic sinusitis, chronic wound infections, and device- associated infections.

Chemotaxis and Immune Cell Recruitment

LL-37 exhibits chemotactic activity for multiple immune cell populations, including neutrophils, monocytes, T cells, mast cells, and eosinophils. This activity is mediated through receptors such as formyl peptide receptor-like 1 (FPRL1) and related signaling pathways. Through these interactions, LL-37 contributes to the directed recruitment of immune cells toward sites of tissue damage or microbial exposure.

Benefits

Broad-Spectrum Antimicrobial Activity

LL-37 is effective against a wide range of pathogens, including gram-positive bacteria (Staphylococcus, Streptococcus), gram-negative bacteria (E. coli, Pseudomonas, Klebsiella), fungi (including Candida species), and enveloped viruses. This broad activity makes it valuable when the specific pathogen is unknown or when dealing with polymicrobial infections.

Biofilm Disruption

Chronic infections often involve biofilms that are 100 to 1,000 times more resistant to antibiotics than free-floating bacteria. LL-37 can penetrate and disrupt biofilm structures, exposing bacteria to immune clearance. This has implications for conditions such as chronic sinusitis, chronic wound infections, and device-associated infections.

Wound Healing

Clinical trials in venous leg ulcers demonstrated that topical LL-37 accelerated wound closure. The peptide promotes re-epithelialization by stimulating keratinocyte migration, enhances angiogenesis to improve blood supply to the wound bed, and provides antimicrobial protection against wound infection. LL-37 activates intracellular signaling pathways such as MAPK and PI3K/Akt and transactivates epidermal growth factor receptor (EGFR) pathways. Reduced expression of LL-37 has been observed in chronic, non-healing wound models, reinforcing its relevance in normal tissue repair processes.

Immune Modulation

Rather than simply suppressing or stimulating the immune system, LL-37 helps regulate immune responses. It enhances pathogen clearance while also neutralizing bacterial toxins that could trigger excessive inflammation. This balanced approach is valuable in chronic inflammatory conditions. LL-37 has been shown to modulate macrophage activation states and regulate cytokine networks, positioning it as an important tool for studying innate immune regulation.

Synergy with Antibiotics

Studies show that LL-37 works synergistically with various antibiotics, including beta-lactams, vancomycin, and others. The peptide disrupts bacterial membranes, allowing antibiotics better access to their intracellular targets. This can help overcome resistance in some cases.

Endotoxin Neutralization

LL-37 binds and neutralizes lipopolysaccharide (LPS), the bacterial endotoxin responsible for septic shock. This protective effect against endotoxemia has been demonstrated in animal models. The ability of LL-37 to bind to and interfere with LPS means it is exceptionally effective against certain gram-negative bacteria.

What the Science Shows

LL-37 has substantial research support, including human clinical trials for topical wound healing applications and extensive preclinical data across multiple therapeutic domains.

Venous Leg Ulcer Trial (Grönberg et al., 2014) A randomized controlled trial tested topical LL-37 in patients with hard-to-heal venous leg ulcers:

group

Antimicrobial Activity Studies

Extensive laboratory research demonstrates LL-37 activity against:

Anti-Biofilm Research (Overhage et al., 2008; Dean et al., 2011) Multiple studies have confirmed LL-37’s ability to prevent bacterial biofilm formation and disrupt established biofilms. Overhage et al. demonstrated that LL-37 prevents biofilm formation by Pseudomonas aeruginosa at sub-inhibitory concentrations. Dean et al. showed antimicrobial and antibiofilm activity against Staphylococcus aureus using both natural and synthetic cathelicidin peptides.

Vitamin D Connection

Research has established that vitamin D regulates LL-37 expression through the cathelicidin gene promoter. This helps explain why vitamin D deficiency is associated with increased infection susceptibility. Studies show that adequate vitamin D status supports natural LL-37 production, providing a mechanistic link between vitamin D levels and innate immune defense.

Immunomodulatory Research

Research by Kahlenberg and Kaplan (2013) established LL-37’s role in inflammation and autoimmune disease, demonstrating that the peptide’s effects are context-dependent and influenced by the local inflammatory environment. Alexandre-Ramos et al. showed that LL-37 treatment on human peripheral blood mononuclear cells modulates immune response and promotes regulatory T-cell generation, suggesting applications in immune balance.

Limitations Noted in Research

Several challenges have been identified in the published literature:

presence of serum proteins These limitations have driven research into LL-37 analogs with improved stability and reduced toxicity.

Dosing Protocol

LL-37 dosing varies significantly based on the route of administration and intended application.

Understanding the Dose Context

Clinical wound healing trials used topical application at 0.5 to 1.6 mg/mL concentrations. Injectable protocols are based on community experience and preclinical research, as human clinical trials for injectable LL-37 have not been published. LL-37 becomes cytotoxic (harmful to host cells) at concentrations above approximately 4.5 to 45 mcg/mL (1 to 10 micromolar). Dosing protocols stay well below these thresholds.

Injectable Protocol (Community Consensus) For systemic immune support or infection: Protocol Dose Frequency Duration Conservative 100 mcg Daily 2 to 4 weeks Standard 100 to 200 mcg Daily 4 to 6 weeks Intensive 200 mcg Twice daily 2 to 4 weeks

Some practitioners use 125 mcg daily for up to 50 days, followed by a 2- to 4-week break before repeating if needed.

Weight-Based Protocol

An alternative approach uses 50 mcg per kilogram of body weight daily. For an 80 kg individual, this would be 4 mg (4,000 mcg) daily, which is significantly higher than fixed-dose protocols and should be approached cautiously.

Topical Protocol (Based on Clinical Trials) For wound healing applications:

Protocol Concentration Application Frequency Standard 0.5 mg/mL 25 mcL per cm² Twice weekly Intensive 1.6 mg/mL 25 mcL per cm² Twice weekly

The 0.5 mg/mL concentration showed optimal results with fewer local reactions in clinical trials.

Why Dose Conservatively

LL-37 is a potent immune stimulator. Excessive dosing can cause:

Start at the lower end of the dose range and assess response before increasing.

Draw Volumes by Vial Size

5 mg Vial (2 mL reconstitution = 2.5 mg/mL = 2,500 mcg/mL)

Dose Volume Units on Syringe 100 mcg 0.04 mL 4 units 125 mcg 0.05 mL 5 units 200 mcg 0.08 mL 8 units 500 mcg 0.20 mL 20 units

5 mg Vial (1 mL reconstitution = 5 mg/mL = 5,000 mcg/mL) Dose Volume Units on Syringe 100 mcg 0.02 mL 2 units 125 mcg 0.025 mL 2.5 units 200 mcg 0.04 mL 4 units 500 mcg 0.10 mL 10 units

At 125 mcg daily with a 5 mg vial, one vial provides 40 days of dosing.

Reconstitution Instructions

1. Remove the plastic cap from the vial and wipe the rubber stopper with an alcohol swab. 2. Draw 1 to 2 mL of bacteriostatic water into a sterile syringe. 3. Insert the needle through the rubber stopper at an angle. 4. Direct the stream of water down the inside wall of the vial, not directly onto the powder. 5. Allow the water to gently dissolve the peptide without shaking or swirling aggressively. 6. If any powder remains undissolved after 2 to 3 minutes, gently roll the vial between your palms. 7. The solution should be clear and colorless when fully reconstituted. 8. Label the vial with the date and concentration. LL-37 is a larger peptide and may require slightly more time to dissolve than smaller compounds. Be patient and allow adequate dissolution time.

Side Effects and Cautions

Common Side Effects

Injection site reactions are the most frequently reported:

These reactions are due to LL-37’s local immune-stimulating effects and typically resolve within hours.

Systemic Effects

Some users report flu-like symptoms, particularly during the first few days:

This is thought to result from cytokine release as LL-37 activates immune cells. Starting at lower doses and titrating up can minimize these effects.

Potential Concerns

lupus). Supplementation may theoretically worsen these conditions.

Contraindications and Precautions

Who Should Avoid LL-37

where LL-37 dysregulation is implicated

Use with Care

Comparison to Similar Compounds

Compound Type Primary Use Route Stability LL-37 Human Antimicrobial Subcutaneous Moderate cathelicidin Defensins Human AMPs Antimicrobial Various Moderate KPV Anti-inflammatory Gut/skin healing Subcutaneous Good

Thymosin α1 Immune Immune support Subcutaneous Good modulator

LL-37 is unique among these compounds for its broad-spectrum antimicrobial activity and biofilm-disrupting capability. KPV and Thymosin Alpha-1 offer complementary immune support through different mechanisms. For chronic infections involving biofilms, LL-37 may offer advantages over other immune peptides due to its direct antimicrobial and biofilm-penetrating properties.

Success Tips

Support Natural Production

The body produces LL-37 naturally. Supporting this endogenous production amplifies the effects of supplementation:

60 ng/mL) support natural LL-37 production.

deprivation.

Use for Targeted Purposes

LL-37 is most valuable for specific applications:

LL-37 is not designed for indefinite daily use.

Consider Stacking for Healing

For wound healing or gut repair, LL-37 pairs well with:

Monitor for Inflammatory Reactions

Because LL-37 activates immune signaling, watch for signs of excessive inflammation. If symptoms worsen rather than improve, reduce the dose or discontinue use.

Foundation First

Peptides support immune function. They do not replace the fundamentals: adequate sleep, stress management, whole food nutrition, and regular exercise. An optimized foundation allows peptides to work more effectively.

Storage and Handling

Before Reconstitution

After Reconstitution

LL-37 is susceptible to proteolytic degradation. Handle carefully and minimize temperature fluctuations.

Legal Status

United States: Not FDA-approved for clinical use. Available through research chemical suppliers for research purposes. Clinical Development: LL-37 and its analogs have been tested in human clinical trials for wound healing applications. Various modified versions continue in development. International: Available for research purposes in most countries. Not approved for clinical use.

Frequently Asked Questions

How is LL-37 different from antibiotics? Antibiotics typically target specific bacterial proteins or enzymes. Bacteria can develop resistance by mutating these targets. LL-37 kills bacteria by disrupting their cell membranes, a fundamental structure that cannot be easily changed without compromising bacterial viability. This makes resistance development less likely. Additionally, LL-37 modulates the immune response rather than simply killing bacteria, providing multilayered protection. Can I use LL-37 instead of antibiotics? LL-37 is not a replacement for antibiotics when they are indicated. It is best viewed as complementary support for immune function. For serious bacterial infections, appropriate medical treatment is essential. LL-37 may be useful for chronic low-grade infections, immune support during illness recovery, or situations where antibiotic resistance is a concern. Will LL-37 help with viral infections? Research shows that LL-37 has activity against enveloped viruses, including influenza and herpes simplex virus. The peptide disrupts viral envelopes and modulates the immune response to viral infection. However, clinical data specifically for viral infections remains limited. Why do some people get flu-like symptoms from LL-37? LL-37 activates immune cells and stimulates cytokine release. This immune activation can cause temporary flu-like symptoms, including fatigue, low-grade fever, and body aches. These effects typically diminish after the first few days as the system adjusts. Starting at lower doses helps minimize this reaction. Can I use LL-37 long term? LL-37 is best used for targeted purposes rather than indefinite daily supplementation. Most protocols run 2 to 6 weeks with breaks between cycles. Chronic use raises theoretical concerns about immune system effects, though long-term safety data does not exist. Does vitamin D affect LL-37 effectiveness? Yes. Vitamin D is a key regulator of cathelicidin expression. Adequate vitamin D status supports natural LL-37 production and may enhance the effectiveness of supplementation. Testing and optimizing vitamin D levels (40 to 60 ng/mL) is a reasonable adjunct to LL-37 use.

References

1. Dürr UH, Sudheendra US, Ramamoorthy A. LL-37, the only human member of the cathelicidin family of antimicrobial peptides. Biochimica et Biophysica Acta. 2006;1758(9):1408–1425. 2. Grönberg A, Mahlapuu M, Ståhle M, Whately-Smith C, Heilborn JD. Treatment with LL-37 is safe and effective in enhancing healing of hard-to-heal venous leg ulcers: a randomized, placebo- controlled clinical trial. Wound Repair and Regeneration. 2014;22(5):613–621. 3. Dean SN, Bishop BM, van Hoek ML. Natural and synthetic cathelicidin peptides with antimicrobial and antibiofilm activity against Staphylococcus aureus. BMC Microbiology. 2011;11:114. 4. Overhage J, Campisano A, Bains M, Torfs EC, Rehm BH, Hancock RE. Human host defense peptide LL-37 prevents bacterial biofilm formation. Infection and Immunity. 2008;76(9):4176– 4182. 5. Nijnik A, Hancock RE. Host defence peptides: antimicrobial and immunomodulatory activity and potential applications for tackling antibiotic-resistant infections. Emerging Health Threats Journal. 2009;2:e1. 6. Ridyard KE, Overhage J. The Potential of Human Peptide LL-37 as an Antimicrobial and Anti-Biofilm Agent. Antibiotics (Basel). 2021;10(6):650. 7. Kahlenberg JM, Kaplan MJ. Little peptide, big effects: the role of LL-37 in inflammation and autoimmune disease. Journal of Immunology. 2013;191(10):4895–4901. 8. Alexandre-Ramos DS, et al. LL-37 treatment on human peripheral blood mononuclear cells modulates immune response and promotes regulatory T-cells generation. Biomedicine & Pharmacotherapy. 2018;108:1584–1590. 9. Xhindoli D, Pacor S, Benincasa M, Scocchi M, Gennaro R, Tossi A. The human cathelicidin LL-37 — A pore-forming antibacterial peptide and host-cell modulator. Biochimica et Biophysica Acta. 2016;1858(3):546–566.

Property Support

Our Property Support services are designed to help homeowners, property managers, and businesses maintain safe, clean, and well-functioning properties year-round.

Get In Touch